Item 7.01Regulation FD Disclosure.
On January 11, 2023, Syneos Health, Inc. (the "Company") will give a
presentation to investors at the J.P. Morgan 2023 Healthcare Conference. Among
other topics, the presentation includes updates on the current market
environment. The full text of the presentation is furnished as Exhibit 99.1
hereto.
The information in this Item 7.01, including Exhibit 99.1 furnished hereto,
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Forward-Looking Statements
Except for historical information, all of the statements, expectations, and
assumptions contained in this Current Report on Form 8-K are forward-looking
statements as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the current market environment.
Actual results may differ materially from those explicit or implicit in the
forward-looking statements. Important factors that could cause actual results to
differ materially include, but are not limited to, changes in business
conditions; risks associated with the COVID-19 pandemic; the Company's potential
failure to generate a large number of new business awards and the risk of delay,
termination, reduction in scope, or failure to go to contract of our business
awards; the Company's potential failure to convert backlog to revenue;
fluctuations in the Company's operating results and effective income tax rate;
the impact of potentially underpricing the Company's contracts, overrunning our
cost estimates, or failing to receive approval for or experiencing delays with
documentation of change orders; cyber-security and other risks associated with
the Company's information systems infrastructure; changes and costs of
compliance with regulations related to data privacy; concentration of the
Company's customers or therapeutic areas; the risks associated with doing
business internationally, including risks related to the war in Ukraine;
challenges by tax authorities of the Company's intercompany transfer pricing
policies; the Company's potential failure to successfully increase its market
share, grow its business, and execute its growth strategies; the Company's
ability to effectively upgrade its information systems; the Company's failure to
perform its services in accordance with contractual requirements, regulatory
standards, and ethical considerations; risks related to the management of
clinical trials; the need to hire, develop, and retain key personnel; the impact
of unfavorable economic conditions, including the uncertain international
economic environment, changes in foreign currency exchange rates; effective
income tax rate fluctuations; the Company's ability to protect its intellectual
property; risks related to the Company's acquisition strategy, including its
ability to realize synergies; the Company's relationships with customers who are
in competition with each other; any failure to realize the full value of the
Company's goodwill and intangible assets; risks related to restructuring; the
Company's compliance with anti-corruption and anti-bribery laws; the Company's
dependence on third parties; potential employment liability; impacts from
increasing focus on environmental sustainability and social initiatives; the
Company's ability to utilize net operating loss carryforwards and other tax
attributes; downgrades of the Company's credit ratings; competition in the
biopharmaceutical services industry; outsourcing trends and changes in aggregate
spending and research and development budgets; the impact of, including changes
in, government regulations and healthcare reform; intense competition faced by
our customers from lower cost generic products and other competing products; the
Company's ability to keep pace with rapid technological change; the cost of and
the Company's ability to service its substantial indebtedness; other risks
related to ownership of the Company's common stock; and other risk factors set
forth in the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2021 and other SEC filings, copies of which are available free of
charge on the Company's website at investor.syneoshealth.com. The Company
assumes no obligation and does not intend to update these forward-looking
statements, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Presentation dated January 11, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses